This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - BSFT, AMBA, GOOG, ADT And NVAX Traded By Insiders

Novavax (NVAX) - FREE Research Report

Phillips Barclay A who is SVP, Chief Financial Officer at Novavax bought 9,868 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Chief Financial Officer owned 9,868 shares meaning that the stake was reduced by 100% with the 9,868-share transaction.

Glenn Gregory M who is SVP, Research and Development at Novavax bought 4,102 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Research and Development owned 31,000 shares meaning that the stake was reduced by 15.25% with the 4,102-share transaction.

Wilson Russell P who is SVP, Business Development at Novavax bought 4,900 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Business Development owned 54,900 shares meaning that the stake was reduced by 9.8% with the 4,900-share transaction.

Erck Stanley C who is President and CEO at Novavax bought 11,868 shares at $2.29 on Feb. 4, 2014. Following this transaction, the President and CEO owned 74,868 shares meaning that the stake was reduced by 18.84% with the 11,868-share transaction.

Hahn Timothy Jon who is SVP, Manufacturing & PD at Novavax bought 9,416 shares at $2.29 on Feb. 4, 2014. Following this transaction, the SVP, Manufacturing & PD owned 80,416 shares meaning that the stake was reduced by 13.26% with the 9,416-share transaction.

The shares most recently traded at $5.21, up $2.92, or 56.05% since the insider transaction. Historical insider transactions for Novavax go as follows:

  • 24-Week # shares bought: 100,000

The average volume for Novavax has been 5.4 million shares per day over the past 30 days. Novavax has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 3.52% year-to-date as of the close of trading on Tuesday.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. Currently there are 4 analysts that rate Novavax a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NVAX - FREE

TheStreet Quant Ratings rates Novavax as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full Novavax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

5 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs